The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease.

Ya ZengJianjiao NiFan YuYue ZhouYang ZhaoShuyan LiTiantian GuoLi ChuXi YangXiao ChuXuwei CaiZhengfei Zhu

Published in: Radiation oncology (London, England) (2020)

Among Osimertinib-treated NSCLC patients having oligo-residual lesions, LCT could improve local control and significantly increase PFS, which need to be verified by further investigations.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
newly diagnosed
end stage renal disease
epidermal growth factor receptor
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
bone marrow
stem cells
patient reported outcomes
brain metastases
cell therapy